Cognition enhancers in age-related cognitive decline

Drugs and Aging

Volumn 8, Issue 4, 1996, Pages 245-274

  Riedel, Wim J ^a   Jolles, Jellemer ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ALCOHOL; ALMITRINE; ARGIPRESSIN[DEGLYCINAMIDE]; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CORTICOTROPIN; DEXAMPHETAMINE; ERGOT ALKALOID; FLUMAZENIL; GUANFACINE; HUPERZINE A; METHYLXANTHINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; NICOTINE; NOOTROPIC AGENT; ONDANSETRON; PIRACETAM; PROTIRELIN; PYRIDOXINE; SCOPOLAMINE; SEROTONIN ANTAGONIST; UNINDEXED DRUG; VITAMIN;

ADULT; AGED; AGING; AMNESIA; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ELECTROENCEPHALOGRAM; GABAERGIC SYSTEM; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; META ANALYSIS; MONOAMINERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REVIEW; SLEEP DEPRIVATION;

EID: 0029935696     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608040-00003     Document Type: Review

References (219)

1. Charness N, editor. Aging and human performance. Waterloo, Canada: John Wiley & Sons, 1985
2. Birren JE, Warner Schaie K, editors. Handbook of the psychology of aging. 3rd ed. New York: Van Nostrand Reinhold Company, 1990
3. LaRue A. Aging and Neuropsychological Assessment. New York: Plenum Press, 1992
4. Jolles J, Verhey FRJ, Riedel WJ, et al. Cognitive impairment in elderly people: predisposing factors and implications for experimental drug studies. Drugs Aging 1995; 7: 459-79
5. Masur DM, Sliwinski M, Lipton RB, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427-32
6. McEntee WJ, Crook TH. Age-associated memory impairment: a role for catecholamines. Neurology 1990; 40: 526-30
7. Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994; 55: 2189-94
8. O'Brien JT, Levy R. Age associated memory impairment. BMJ 1992; 304: 5-6
9. Ban TA. Psychopharmacology and succesful cerebral aging. Prog Neuropsych Biol Psychiatry 1994; 19: 1-9
10. Michel B, Sambuc R, Scotto JC. French recommendations for clinical drug trials in cognitive disorders of the elderly. Int J Geriatr Psychiatry 1994; 9: 823-8
11. Frostl W, Maitre L. The families of cognition enhancers. Pharmacopsychiatry 1989; 2: 54-100
12. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. Psychopharmacology 1992; 107: 144-59
13. Cacabelos R, Nordberg A, Caamano J, et al. Molecular strategies for the first generations of antidementia drugs (1). Tacrine and related compounds. Drugs Today 1994; 30: 295-337
14. Porsolt RD. Strategies in psychopharmacology: cognition enhancers - from animals to man: concluding remarks. Pharmacopsychiatry 1990; 23: 99-100
15. Schwartz G, Bisserbe JC, Bradford D, et al. Late clinical testing of cognition enhancers: demonstration of efficacy. Pharmacopsychiatry 1990; 2: 60-2
16. Müller WE, Pedigo NW. Brain aging: a risk factor of neurodegenerative disorders and a target for therapeutic intervention. Life Sci 1994; 55: 1975-6
17. Caine ED. Should aging-associated cognitive decline be included in DSM-IV? J Neuropsychiatry Clin Neurosci 1993; 5: 1-5
18. Giurgea CE. The 'nootropic' approach to the pharmacology of the integrative activity of the brain. Conditional Reflex 1973; 8: 108-15
19. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994; 19: 180-222
20. Sarter M, Hagan J, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. Psychopharmacology 1992; 107: 461-73
21. Giacobini E, Becker R, editor. Alzheimer's disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994
22. Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962; 86: 257-60
23. Crook T, Bartus RT, Ferris SH, et al. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health work group. Dev Neuropsychol 1986; 2: 261-76
24. Blackford RC, LaRue A. Criteria for diagnosing age-associated memory impairment: proposed improvements from the field. Dev Neuropsychol 1989; 5: 295-306
25. Bamford KA, Caine ED. Does 'benign senescent forgetfulness' exist? Clin Geriatr Med 1988; 4: 897-916
26. Tritsmans L, Clincke G, Peelmans B. Does AAMI constitute a real disease entity? A placebo-controlled double-blind study with sabeluzole (R58 735) in a patient population with real memory problems. Drug Dev Res 1990; 20: 473-82
27. Rosen TJ. 'Age-associated memory impairment': a critique. Special issue: cognitive gerontology. Eur J Cogn Psychol 1990; 2: 275-87
28. Smith G, Ivnik RJ, Petersen RC, et al. Age-associated memory impairment diagnosis: problems of reliability and concerns for terminology. Psychol Aging 1991; 6: 551-8
29. Abate G, Angeleri F, Bartorelli L, et al. Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans. Arzneimittelforschung 1992; 42: 1417-21
30. Clincke GH, Tritsmans L, Peelmans B. Long-term follow-up treatment with sabeluzole in elderly patients with pronounced memory problems of unknown origin. Drug Dev Res 1991; 23: 301-5
31. Schmidt U, Brendemuhl D, Engels K, et al. Piracetam in elderly motorists. Pharmacopsychiatry 1991; 24: 121-6
32. Riedel WJ. Cognition enhancing drugs, cholinergic function and age-related decline. Maastricht: Neuropsych Publishers, 1995
33. Hijman R, Jolles J, Verhoeven WMA, et al. Desglycinamide-(Arg(8))-vasopressin in five trials with memory-disturbed patients. Hum Psychopharmacol 1992; 7: 7-23
34. Marini G, Caratti C, Peluffo F. Placebo-controlled double-blind study of pramiracetam (CI-879) in the treatment of elderly subjects with memory impairment. Adv Ther 1992; 9: 136-46
35. Fioravanti M, Bergamasco B, Bocola V, et al. A multicentre, double-blind, controlled study of piracetam vs placebo in geriatric patients with nonvascular mild-moderate impairment in cognition. New Trends Clin Neuropharmacol 1991; V: 27-34
36. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991; 12: 350-5
37. Gamzu ER, Birkhimer LJ, Hoover T, et al. Early human trials in the assessment of cognition activators. Pharmacopsychiatry 1990; 2: 44-8
38. Hall ST, Puech A, Schaffler K, et al. Early clinical testing of cognition enhancers: prediction of efficacy. Pharmacopsychiatry 1990; 2: 57-8
39. Porsolt RD. Strategies in psychopharmacology: cognition enhancers - from animals to man [preface]. Pharmacopsychiatry 1990; 23: 29-30
40. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17
41. Bartus RT, Dean RL, Pontecorvo MJ, et al. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann NY Acad Sci 1985; 444: 332-58
42. Drachman D, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113-21
43. Drachman D, Sahakian B. The effects of cholinergic agents on human learning and memory. In: Bareau A, Growdon J, Wurtman R, editors. Nutrition and the brain. New York: Raven Press, 1979: 351-66
44. Kopelman MD. The cholinergic neurotransmitter system in human memory and dementia: a review. Q J Exp Psychol A 1986; 38: 535-73
45. Kopelman MD, Corn TH. Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988; 111: 1079-110
46. Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 1992; 17: 215-26
47. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82: 147-50
48. Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984; 84: 5-11
49. Wesnes K, Simpson PM, Kidd A. The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Med Sci Res Psychol Psychiatry 1987; 15: 1063-4
50. Preston GC, Ward C, Lines CR, et al. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology 1989; 98: 487-94
51. Nuotto E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. Eur J Clin Pharmacol 1983; 24: 603-9
52. Schmedtje JJ, Oman CM, Letz R, et al. Effects of scopolamine and dextroamphelamine on human performance. Aviat Space Environ Med 1988; 59: 407-10
53. Meador KJ, Loring DW, Lee GP, et al. In vivo probe of central cholinergic systems. J Gerontol 1988; 43: M158-62
54. Kennedy RS, Odenheimer RC, Baltzley DR, et al. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat Space Environ Med 1990; 61: 615-21
55. Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985; 9: 87-94
56. Saner M, Stephens DN. Beta-carbolines as tools in memory research: animal data and speculations. Psychopharmacol Ser 1988; 6: 230-45
57. Sarter M, Schneider HH, Stephens DN. Treatment strategies for senile dementia: antagonist β-carbolines. Trends Neurosci 1988; 11: 13-7
58. 3 antagonists and benzodiazepines. Chichester: Wiley, 1991: 267-80
59. Bahrke MS, Shukitt HB. Effects of altitude on mood, behaviour and cognitive functioning: a review. Sports Med 1993; 16: 97-125
60. Kraaier V, Van Huffelen AC, Wieneke GH. The hyperventilation-induced ischaemia model in human neuropharmacology: neurophysiological and psychometric studies of aniracetam and 3-OH aniracetam. Eur J Clin Pharmacol 1989; 36: 605-11
61. Saletu B, Grünberger J. The hypoxia model in human psychopharmacology: neuropsychological and psychometric studies with aniracetam. Hum Neurobiol 1984; 3: 171-81
62. Weinachter SN, Blavet N, O'Donnell RA, et al. Models of hypoxia and cerebral ischemia. Pharmacopsychiatry 1990; 2: 94-7
63. Hindmarch I, Kerr JS, Sherwood N. The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcohol 1991; 26: 71-9
64. Nilsson LG, Backman L, Karlsson T. Priming and cued recall in elderly, alcohol intoxicated and sleep deprived subjects: a case of functionally similar memory deficits. Psychol Med 1989; 19: 423-33
65. Clausen TG, Wolff J, Carl P, et al. The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990; 38: 233-6
66. Collins WE, Mertens HW. Age, alcohol, and simulated altitude: effects on performance and breathalyzer scores. Aviat Space Environ Med 1988; 59: 1026-33
67. Sanders AF. Towards a model of stress and human performance. Acta Psychol (Amst) 1983; 53: 61-97
68. McCann UD, Penetar DM, Shaham Y, et al. Sleep deprivation and impaired cognition. Possible role of brain catecholamines. Biol Psychiatry 1992; 31: 1082-97
69. Hunt E. What do we need to know about aging? In: Cerella J, Rybash J, Hoyer W, et al., editors. Adult information processing: limits on loss. San Diego: Academic Press Inc, 1993: 587-98
70. Hobus P. Expertise van huisartsen. Praklijkervaring, kennis en diagnostische hypothesevorming. Maastricht: Rijksuniversiteit Limburg, 1994
71. Hijman R. Desglycinamide-(Arg(8))-vasopressin in patients with memory disturbances. Utrecht: University Press, 1992
72. Brand N, Jolles J. Learning and retrieval rate of words presented auditorily und visually. J Gen Psychol 1985; 112: 201-10
73. Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique. Paris: Presses Universitaires de France, 1964
74. Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learning Verbal Behav 1973; 12: 543-50
75. Sternberg S. Memory scanning: mental processes revealed by reaction time experiments. Am Sci 1969; 57: 421-57
76. Verhaeghen P, Marcoen A, Goossens L. Facts and fiction about memory aging: a quantitative integration of research findings. J Gerontol 1993; 48: P157-71
77. Brand N, Jolles J. Information processing in depression and anxiety. Psychol Med 1987; 17: 145-53
78. Saletu B, Anderer P, Kinsperger K, et al. Topographic brain mapping of EEG in neuropsychopharmacology - part II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Pharmacol 1987; 9: 385-408
79. Michel CM, Lehmann D. Single doses of piracetam affect 42-channel event-related potential microstate maps in a cognitive paradigm. Neuropsychobiology 1993; 28: 212-21
80. Wesnes KA, Anand R, Simpson PM, et al. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol 1990; 4: 219-32
81. Zyhlarz G, Saletu B, Hitzenberger G, et al. Double-blind, placebo-controlled, pharmacokinetic and dynamic studies with two new formulations of piracetam (infusion and syrup) under hypoxia in man. Neuropsychopharmacology 1994; 10: 117S
82. Preda L, Alberoni M, Bressi S, et al. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology 1993; 110: 421-6
83. Saletu B, Schulz H, Herrmann WM, et al. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Pharmacopsychiatry 1994; 27: 189-97
84. Saletu B, Grunberger J, Anderer R. On brain protection of codergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 510-24
85. Saletu B, Anderer P, Grunberger J. Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 1990; 11: 1-22
86. Patat A, Klein MJ, Surjus A, et al. RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 225-31
87. Patat A, Klein MJ, Surjus A, et al. Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects. Psychopharmacol Berl 1991; 104: 75-80
88. Bruins J, Kumar A, Schneider Helmert D. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects. Neuropsychobiology 1990; 23: 82-8
89. Bruins J, Hijman R, Van Ree JM. Effect of a single dose of des-glycinamide-[Arg8]vasopressin or oxytocin on cognitive processes in young healthy subjects. Peptides 1992; 13: 461-8
90. Siegfried KR. First clinical impressions with an ACTH analog (HOE 427) in the treatment of Alzheimer's disease. Ann NY Acad Sci 1991; 640: 280-3
91. Wesnes KA, Simpson PM, White L, et al. HOE-427, a cholinergically active neuropeptide, improves cognitive efficiency in the elderly. Biol Psychiatry 1991; 29: 691
92. Molchan SE, Mellow AM, Lawlor BA, et al. TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 1990; 100: 84-9
93. Glue P, Bailey J, Wilson S, et al. Thyrotropin-releasing hormone selectively reverses lorazepam-induced sedation but not slowing of saccadic eye movements. Life Sci 1992; 50: P125-30
94. Wesnes KA, Simpson PM, White L, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann NY Acad Sci 1991; 640: 268-71
95. Wallnöfer A, Prescott J, Malek N, et al. Physostigmine improves cognitive performance and alters EEG in healthy volunteers - an approach to study central cholinergic effects. Neuropsychopharmacology 1994; 10: 39S
96. Wesnes KA, Simpson P, Christmas L, et al. Effects of HP029 in a scopolamine model of ageing and dementia. 17th Congress of C.I.N.P.: 1990 Sep 9-13; Kyoto, 235
97. Lines CR, Ambrose JH, Heald A, et al. A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects. Hum Psychopharmacol 1993; 8: 271-8
98. Brass EP, Polinsky R, Sramek JJ, et al. Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol 1995, 15: 58-62
99. Rusted J, Eaton-Williams P. Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall. Psychopharmacology 1991; 104: 363-6
100. Hindmarch I, Kerr JS, Sherwood N. Effects of nicotine gum on psychomotor performance in smokers and non-smokers. Psychopharmacology 1990; 100: 535-41
101. Kerr JS, Sherwood N, Hindmarch I. Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology Berl 1991; 104: 113-9
102. Newhouse PA, Penetar DM, Fertig JB, et al. Stimulant drug effects on performance and behavior after prolonged sleep deprivation: a comparison of amphetamine, nicotine, and deprenyl. Mil Psychol 1992; 4: 207-33
103. Rusted J, Graupner L, O'Connell N, et al. Does nicotine improve cognitive function? Psychopharmacology 1994; 115: 547-9
104. Le Houezec J, Halliday R, Benowitz NL, et al. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology 1994; 114: 628-34
105. Riedel WJ, Hogervorst E, Leboux RLAM, et al. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 1995; 122: 158-68
106. Soetens E, D'Hooge R, Hueting JE. Amphetamine enhances human-memory consolidation. Neurosci Lett 1993; 161: 9-12
107. Vincent A, Risinger R, Schmidt M, et al. Cognitive effects of idazoxan in normal volunteers. Neuropsychopharmacology 1994; 10: 115S
108. 3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects. Br J Clin Pharmacol 1992; 33: 546
109. Wesnes K, Anand R, Lorscheid T. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand Suppl 1990; 360: 71-2
110. Curran HV, Birch B. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil. Psychopharmacol Berl 1991; 103: 519-23
111. Ghoneim MM, Block RI, Ping ST, et al. The interactions of midazolam and flumazenil on human memory and cognition. Anesthesiology 1993; 79: 1183-92
112. Hommer D, Weingartner HJ, Breier A. Dissociation of benzo-diazepine-induced amnesia from sedation by flumazenil pretreatment. Psychopharmacology 1993; 112: 455-60
113. Duka T, Edelmann V, Schutt B, et al. Scopolamine-induced amnesia in humans: lack of effects of the benzodiazepine receptor antagonist β-carboline ZK 93426. J Psychopharmacol 1992; 6: 382-8
114. Jones RW, Wesnes KA, Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann NY Acad Sci 1991; 640: 241-4
115. Wesnes K, Jones RW, Kirby J, et al. D-Cycloserine antagonizes scopolamine induced memory impairments and improves memory in the elderly. Biol Psychiatry 1991; 29: 700S
116. Wesnes K, Jones RW, Kirby J. The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. Br J Clin Pharmacol 1991; 31: 577-8
117. Camp-Bruno JA, Herting RL, Winsberg BG. Milacemide effects on memory and vigilance. Biol Psychiatry 1991; 29: 286
118. Yu G, Maskray V, Jackson SH, et al. A comparison of the central nervous system effects of caffeine and theophylline in elderly subjects. Br J Clin Pharmacol 1991; 32: 341-5
119. Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol 1992; 70: 286-9
120. Hasenfratz M, Bunge A, Dal Pra G, et al. Antagonistic effects of caffeine and alcohol on mental performance parameters. Pharmacol Biochem Behav 1993; 46: 463-5
121. Rush CR, Higgins ST, Hughes JR, et al. Acute behavioral effects of triazolam and caffeine, alone and in combination, in humans. Exp Clin Psychopharmacol 1994; 2: 211-22
122. Lorist MM, Snel J, Kok A, et al. Influence of caffeine on selective attention in well rested and fatigued subjects. Psychophysiology 1994; 31: 525-34
123. Lorist MM, Snel J, Kok A. Influence of caffeine on information processing stages in well rested and fatigued subjects. Psychopharmacology 1994; 113: 411-21
124. Tiplady B, Fagan D, Lamont M, et al. A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures. Br J Clin Pharmacol 1990; 30; 55-61
125. Meador KJ, Nichols ME, Franke P, et al. Evidence for a central cholinergic effect of high-dose thiamine. Ann Neurol 1993; 34: 724-6
126. Benton D, Owens DS. Blood glucose and human memory. Psychopharmacology 1993; 113: 83-8
127. Rosadini G, Sannita WG, Nobili F, et al. Phosphatidylserine: quantitative EEG effects in healthy volunteers. Neuropsychobiology 1990; 24: 42-8
128. Ladd SL, Sommer SA, LaBerge S, et al. Effect of phosphatidylcholine on explicit memory. Clin Neuropharmacol 1993; 16: 540-9
129. Meyer FP. Influence of nifedipine on human performance following a single dose - differential psychopharmacological aspects. Hum Psychopharmacol 1994; 9: 93-100
130. Lines CR, Preston GC, Dawson CE, et al. The effects of pretreatment with enalapril maleate on scopolamine-induced cognitive deficits in healthy volunteers. J Psychopharmacol 1991; 5: 228-33
131. Israel L, Melac M, Milinkevitch D, et al. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int Psychogeriatr 1994; 6: 155-70
132. Mauri M, Sinforiani E, Reverberi F, et al. Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. Arch Gerontol Genatr 1994; 18: 133-9
133. Dodt C, Pietrowsky R, Sewing A, et al. Effects of vasopressin on event-related potential indicators of cognitive stimulus processing in young and old humans. J Gerontol 1994; 49: M183-8
134. Wang Z-X, Ren Q-Y, Shen Y-C. A Double-blind, control study of huperzine A and piracetam in patients with age-associated memory impairment and Alzheimer's disease. Neuropsychopharmacology 1994; 10: 763S
135. Saletu B, Darragh A, Breuel HP, et al. EEG mapping central effects of multiple doses of linopirine - a cognitive enhancer in healthy elderly male subjects. Hum Psychopharmacol 1991; 6: 267-75
136. McEntee WJ, Crook TH, Jenkyn LR, et al. Treatment of age-associated memory impairment with guanfacine. Psychopharmacol Bull 1991; 27: 41-6
137. Poitrenaud J, Piette F, Malbezin M, et al. Almitrine-raubasine and cognitive impairment in the elderly: results of a 6-month controlled multicenter study. Clin Neuropharmacol 1990; 13: 100-8
138. Wesnes K, Neuman E, De Wilde HJG, et al. Pharmacodynamic effects of repeated oral administration of 4 different doses of S12024-2 (cognitive enhancer) in 36 healthy elderly volunteers. Neurobiol Aging 1994; 15: 100
139. Crook TH, Lakin M. Effects of ondansetron in age-associated memory impairment. Biol Psychiatry 1991; 2: 888-90
140. Searle & Co. Mullicenter, randomized, double-blind study of 1 mg, 5 mg and 15 mg b.i.d. of cycloserine vs placebo in the treatment of age-associated memory impairment [technical report]. 1993, EC 6-93-02-007
141. Schwanrtz BL, Hashtroudi S, Herting RL, et al. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991; 41: 1341-3
142. Benton D, Fordy J, Haller J. The impact of long-term vitamin supplementation on cognitive functioning. Psychopharmacology 1995; 117: 298-305
143. Deijen JB, Van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology 1992; 109: 489-96
144. Hindmarch I, Coleston DM, Kerr JS. Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology 1990; 24: 159-64
145. Künkel H. EEG profile of three different extractions of ginkgo biloba. Neuropyschobiology 1993; 27: 40-5
146. Münte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46-53
147. Saletu B, Grunberger J, Linzmayer L, et al. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative actovegin: double-blind, placebo-controlled trials. Neuropsychobiology 1990; 24: 135-48
148. Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41: 644-9
149. Sudilovsky A, Crook T, Repetti S, et al. Angiotensin converting enzyme inhibitors (ACEI) and cognitive functioning in animals and man. Biol Psychiatry 1991; 29: 287
150. Bruce-Jones PN, Crome P, Kalra L. Indomethacin and cognitive function in healthy elderly volunteers. Br J Clin Pharmacol 1994; 38: 45-51
151. Vernon MW, Sorkin EM. Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991; 1: 17-35
152. Mondadori C. In search of the mechanism of action of the nootropics: new insights and potential clinical implications. Life Sci 1994; 55: 2171-8
153. Stelmach GE, Zelaznik HN, Lowe D. The influence of aging and attentional demands on recovery from postural instability. Aging 1990; 2: 155-61
154. Teasdale N, Bard C, LaRue J, et al. On the cognitive penetrability of posture control. Exp Aging Res 1993; 19: 1-13
155. Wadworth AN, Chrisp P. Co-dergocrine mesylate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging 1992; 2: 153-73
156. Jolles J. Vasopressin and human behavior. In. Gash DM, Boer GJ, editors. Vasopressin, principles and properties. New York: Plenum Press, 1987: 549-78
157. McEntee WJ, Crook TH. Cholinergic function in the aged brain: implications for treatment of memory impairments associated with aging. Behav Pharmacol 1992; 3: 327-36
158. Bodick NC, DeLong AF, Bonate PL, et al. Xanomeline, a specific M1 agonist: early clinical studies. In: Giacobini E, Becker RE, editors. Alzheimer's disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994: 234-8
159. Sahakian B, Jones GMM, Levy R, et al. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989; 154: 797-800
160. Jones GMM, Sahakian BJ, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992; 108: 485-94
161. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4: 510-40
162. Giacobini E, Becker R. Development of drugs for Alzheimer therapy: a decade of progress. In: Giacobini E, Becker RE, editor. Alzheimer's disease: therapeutic strategies. Basel: Birkhäuser Verlag AG, 1994: 1-7
163. Van Duijn M, Hofman A. Relation between nicotine intake and Alzheimer's disease. BMJ 1991; 302: 1491-4
164. Newhouse PA, Potter A, Corwin J, et al. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacol Berl 1992; 108: 480-4
165. Newhouse PA, Potter A, Corwin J, et al. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994; 10: 93-107
166. McGehee D, Heath M, Gelber S, et al. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995; 269: 1692-6
167. 2-noradrenergic system: effects on cognition. Drugs Aging 1994; 5: 116-26
168. Robbins T, Everitt B. Arousal systems and attention. In: Gazzangia M, editor. The cognitive neurosciences. Cambridge (MA): MIT Press, 1995: 703-20
169. McEntee WJ, Crook TH. Serotonin, memory, and the aging brain. Psychopharmacol Berl 1991; 103: 143-9
170. Porsolt RD. Serotonin: neurotransmitter 'a la mode'. Report on the Third International I.T.E.M. -LABO symposium on strategies in psychopharmacology. Serotonin: animal models and clinical targets. Pharmacopsychiatry 1993; 26: 20-4
171. Muller T, Kuhn W, Przuntek H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm Gen Sect 1993; 92: 187-95
172. Stoll S, Hafner U, Pohl O, et al. Age-related memory decline and longevity under treatment with selegiline. Life Sci 1994; 55: 2155-63
173. Houx PJ, Vreeling FW, Jolles J. Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993; 19: 209-24
174. Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer's disease. Arch Gen Psychiatry 1987; 44: 427-33
175. Schneider LS, Tariot PN, Goldstein B. Therapy with 1-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994; 56: 750-6
176. Ziegler G, Ludwig L, Fritz G. Effect of the specific benzodiazepine antagonist Ro 15-1788 on sleep. Pharmacopsychiatry 1986; 19: 200-1
177. O'Hanlon JF, Vermeeren A. Effects of Ro 15-1788 on the vigilance performance of sleep-deprived men. Hum Psychopharmacol 1988; 3: 267-74
178. Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann NY Acad Sci 1991; 640: 237-40
179. Müller WE, Scheuer K, Stoll S. Glutamatergic treatment strategies for age-related memory disorders. Life Sci 1994; 55: 2147-53
180. Markowitsch H. Intellectual functions and the brain. An historical perspective. Seattle. Hogrefe and Huber, 1992
181. Lieberman HR, Wurtman RJ, Emde GG, et al. The effects of low doses of caffeine on human performance and mood. Psychopharmacology 1987; 92: 308-12
182. Biaggioni I, Subir P, Puckett A, et al. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991; 258: 588-93
183. Swift CG, Tiplady B. The effects of age on the response to caffeine. Psychopharmacology 1988; 94: 29-31
184. Stavric B. An update on research with coffee/caffeine (1989-1990). Food Chem Toxicol 1992; 30: 533-5
185. Nehlig A, Daval J-L, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 1992; 17: 139-70
186. Briley M. Biochemical strategies in the search for cognition enhancers. Pharmacopsychiatry 1990; 2: 75-80
187. Jarvis M. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology 1993; 110: 45-52
188. Benton D. Vitamin-mineral supplements and intelligence. Proc Nutr Soc 1992; 51: 295-302
189. 12 are related to decreased performance of healthy subjects in the Stroop Color Word Test. Neurosci Res Commun 1992; 11: 53-6
190. Loriaux SM, Deijen JB, Orlebeke JF, et al. The effects of nicotinic acid and xanthinol nicotate on human memory in different categories of age. Psychopharmacology 1985; 87: 390-5
191. 6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry 1991; 29: 931-41
192. Micheau J, Durkin TP, Destrade C, et al. Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav 1985; 23: 195-8
193. Consolis S, Mas M. Intérêt d'un antiasthénique polyvalent, Arcalion 200 sur la vigilance et le stress des sportifs en haute compétition [in French]. Psychol Med 1988; 20: 2
194. Israel L, Dell'Acio E, Hugonot R. Arcalion 200 entraînement mental. Intérêts d'Arcalion 200 chez les personnes âgées asthéniques. Journale de Médecine Pratique 1989; Suppl. 1: 19-24
195. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34: 352-8
196. Kieijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136-9
197. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11
198. Semlitsch HV, Anderer P, Saletu B, et al. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology 1990; 24: 49-56
199. O'Brien AJ, Bulpitt CJ. The effects of ACE inhibitors on cognitive function. Drugs Aging 1995; 6: 173-80
200. Wenk GL. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology 1989; 99: 431-8
201. Benton D, Sargent J. Breakfast, blood glucose and memory. Biol Psychol 1992; 33: 207-10
202. Guez D, Malbezin M, Neuman E, et al. S12024, a new drug in development for the treatment of Alzheimer's disease. Update on dementia and functional disorders in old age; 1994 Jul 13-14: London
203. Houx PJ, Vreeling FW, Jolles J. Rigorous health screening reduces age effect on memory scanning task. Brain Cogn 1991; 15: 246-60
204. Bohnen NI, Twijnstra A, Jolles J. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. Neurology 1993; 43: 103-6
205. Saletu B, Saletu M, Grünberger J, et al. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology 1993; 27: 26-39
206. Aldenkamp AP, Wieringen Av, Alpherts WCJ, et al. Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy. Neuropsychobiology 1990; 24: 90-101
207. Somnier FE, Ostergaard MS, Boysen G, et al. Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents. A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests. Psychopharmacology 1990; 101: 43-6
208. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17: 485-95
209. Gaillard A. The evaluation of drug effects in laboratory tasks. In: Hindmarch I, Aufdembrinke B, Ott H, editors. Psychopharmacology and reaction time. Chichester: John Wiley & Sons, 1988: 15-24
210. Riedel WJ, Hamers HMW, Robbe HWJ, et al. Automated behavioral testing in psychotropic drug research. In: Mulder LJM, Maarse FJ, Sjouw WPB, et al., editors. Computers in psychology: applications in education, research and psychodiagnostics. Amsterdam: Swets & Zeitlinger, 1991: 166-70
211. Larrabee GJ, Crook T. A computerized everyday memory battery for assessing treatment effects. Psychopharmacol Bull 1988; 24: 695-7
212. Simpson PM, Surmon DJ, Wesnes KA, et al. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991; 6: 95-102
213. Jolles J. Aging of brain & behavior: biomedical, clinical and behavioral research in the domain of aging at the University of Limburg. In: Van Bezooijen CFA, Ravid R, Verhofstad AAJ, editors. From gene to man. The Hague: J.H. Pasmans Publishers, 1990: 146-50
214. Rusted J. Cholinergic blockade and human information processing: are we asking the right questions? J Psychopharmacol 1994; 8: 54-9
215. 1 antagonist biperiden in healthy human volunteers. Biol Psychiatry 1993; 33: 188-93
216. File SE, Goodall EM, Mabbutt PS, et al. State-dependent retrieval and midazolam. Hum Psychopharm 1993; 8: 243-51
217. Birch B, Curran HV. The differential effects of flumazenil on the psychomotor and amnesic actions for midazolam. J Psychopharmacol 1990; 4: 29-34
218. Rother M, Kessler J, Funke M, et al. Memory impairment after hyperventilation-a physiological model of cognitive dysfunctions. Neurobiol Aging 1994; 15: 92
219. Stoppe G, Sandholzer H, Staedt J, et al. Reasons for prescribing cognition enhancers in primary care: results of a representative survey in Lower Saxony, Germany. Int J Clin Pharmacol Ther 1995; 33: 486-90